Kocak Ulker, Gursel Turkiz, Kaya Zuhre, Aral Yusuf Ziya, Albayrak Meryem, Keskin Ebru Yılmaz, Belen Burcu, Isık Melek, Oner Nergiz
Unit of Pediatric Hematology, Department of Pediatrics, Gazi University School of Medicine, Ankara, Turkey.
Pediatr Hematol Oncol. 2012 Mar;29(2):130-40. doi: 10.3109/08880018.2011.629859.
Little is known about the likelihood of curing children with high-dose chemotherapy regimens for treatment of childhood acute lymphoblastic leukemia (ALL) in Turkey. The authors here report their 13 years' experience with original ALL-BFM (Berlin-Franfurt-Münster) 95 protocol in a cohort of 140 Turkish children with ALL. Complete remission rate was 97.7% with a relapse rate of 12.9% and death rate 17.9% during a median follow-up of 69 months. The event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) in these patients at 12 years were 75.0%, 87.1%, and 80.6%, respectively. These results show that ALL-BFM 95 protocol is equally applicable in the experienced centers, even in developing countries without substantial treatment-related toxicity. High rate of infection deaths are to be reduced with correct policies.
关于在土耳其采用高剂量化疗方案治疗儿童急性淋巴细胞白血病（ALL）时治愈儿童的可能性，人们了解甚少。本文作者报告了他们在140名患有ALL的土耳其儿童队列中采用原始ALL-BFM（柏林-法兰克福-明斯特）95方案的13年经验。在中位随访69个月期间，完全缓解率为97.7%，复发率为12.9%，死亡率为17.9%。这些患者12年时的无事件生存率（EFS）、无病生存率（DFS）和总生存率（OS）分别为75.0%、87.1%和80.6%。这些结果表明，ALL-BFM 95方案在经验丰富的中心同样适用，即使在没有严重治疗相关毒性的发展中国家也是如此。通过正确的政策可降低高感染死亡率。
